{
    "Trade/Device Name(s)": [
        "Abbott Carbamazepine Assay"
    ],
    "Submitter Information": "Thermo Fisher Scientific, Clinical Diagnostics Division",
    "510(k) Number": "K123518",
    "Predicate Device Reference 510(k) Number(s)": [
        "K993028"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "KLT"
    ],
    "Summary Letter Date": "June 5, 2013",
    "Summary Letter Received Date": "April 30, 2013",
    "Submission Date": "April 26, 2013",
    "Regulation Number(s)": [
        "21 CFR 862.3645"
    ],
    "Regulation Name(s)": [
        "Neuroleptic drugs radioreceptor assay test system"
    ],
    "Analyte Class(es)": [
        "tdm",
        "toxicology"
    ],
    "Analyte(s)": [
        "Carbamazepine"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Glass tube",
        "Plastic tube",
        "Serum separator tube (SST)",
        "Sodium fluoride/potassium oxalate tube",
        "Sodium heparin tube",
        "Lithium heparin tube",
        "Gel tube",
        "K3 EDTA tube",
        "K2 EDTA tube",
        "Sodium citrate tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ARCHITECT cSystems"
    ],
    "Method(s)/Technology(ies)": [
        "Particle-enhanced turbidimetric inhibition immunoassay (PETINIA)"
    ],
    "Methodologies": [
        "Turbidimetric immunoassay",
        "Competitive immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Reagent",
        "Component"
    ],
    "Document Summary": "FDA 510(k) summary for Abbott Carbamazepine Assay using PETINIA technology on ARCHITECT cSystems for quantitative measurement of carbamazepine in serum and plasma",
    "Indications for Use Summary": "For in vitro quantitative measurement of carbamazepine in human serum or plasma on the ARCHITECT cSystems to monitor therapeutic drug levels",
    "fda_folder": "Toxicology"
}